## SRPT: Sarepta Therapeutics, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.5% below STRENGTH zone (4.0-10.0%); PEG 159.25 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (57% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($19.68)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bearish (Bullish: 0, Bearish: 4)

**1. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation**
- Source: FOX 2 | 20251227T140949 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sarepta Therapeutics, Inc. (SRPT) after the company announced on November 3, 2025, that its ESSENCE trial for two gene therapies did not meet its primary endpoint, causing a significant drop in its stock price. The firm is encouraging investors who purchased Sarepta securities to learn more about the investigation and potentially participate. This legal action aims to recover investor capital and ensure corporate accountability.

**2. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation**
- Source: KSNT 27 News | 20251226T140934 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sarepta Therapeutics, Inc. (SRPT) following a significant drop in its stock price. This decline occurred after Sarepta announced on November 3, 2025, that its late-stage ESSENCE trial for two Duchenne muscular dystrophy gene therapies, AMONDYS 45 and VYONDYS 5, did not meet its primary endpoint, causing a 33.74% share price fall. The firm is encouraging investors who purchased Sarepta securities to join the investigation.

**3. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation**
- Source: Fox 59 | 20251226T110000 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating Sarepta Therapeutics, Inc. (SRPT) after the company disclosed that its ESSENCE trial for two Duchenne muscular dystrophy gene therapies did not meet its primary endpoint, causing a significant stock price drop. The firm encourages investors who purchased Sarepta securities to join the investigation. This aims to recover investor capital and ensure corporate accountability.

**4. Assenagon Asset Management S.A. Sells 838,457 Shares of Sarepta Therapeutics, Inc. $SRPT**
- Source: MarketBeat | 20251226T090817 | Somewhat-Bearish | Relevance: 100%
- Assenagon Asset Management S.A. significantly reduced its stake in Sarepta Therapeutics by selling 838,457 shares, leaving them with 29,482 shares valued at approximately $568,000. Despite a brutal year for Sarepta with a Q3 EPS miss and a 14.5% YoY revenue decline, analysts maintain a "Hold" consensus rating with a target price of $33.68, suggesting a potential 179% upside. Other institutional investors like Ancora Advisors LLC, Banque Transatlantique SA, and AlphaQuest LLC have also adjusted their positions, with insiders owning 7.60% of the company's stock.

**5. Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Connect**
- Source: ABC27 | 20251225T150818 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Sarepta Therapeutics, Inc. (SRPT) on behalf of investors. This investigation follows Sarepta's disclosure on November 3, 2025, that its ESSENCE trial for two Duchenne muscular dystrophy gene therapies did not meet its primary endpoint, causing a significant drop in their stock price. The firm encourages affected investors to connect with them for more information.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Wedbush | $32 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Wedbush | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 4 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 12.6% (+8.9%)
- Vanguard Group Inc: 10.3% (+18.1%)
- State Street Corpora: 5.1% (+13.0%)
- Erste Asset Manageme: 2.6% (+65.7%)
- Renaissance Technolo: 2.5% (+324.4%)

### Key Risks

1. Valuation stretched: PEG 159.2x requires aggressive growth execution.
2. High short interest (22.3%, 5.8 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 27.4% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 159.25 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.0x). Revenue declining -25% YoY, concerning. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.3B |
| Beta | 0.53 |
| 52W Range | $10.42 - $129.84 |
| Short Interest | 22.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 159.25 |
| Forward P/E | 7.9 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -0.4% to 1.5% (+1.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Below SMA200 (0.73x), long-term trend not supportive. RSI neutral at 56. Volume at 57% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.47% (CS: 71) | Neutral |
| RSI_14 | 56.1 | Neutral |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 1.024x | Above |
| vs SMA50 | 1.064x | Above |
| vs SMA200 | 0.726x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $22.12
- **Stop Loss:** $19.68 (11.0% risk)
- **Target:** $24.56 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 540
- **Position Value:** $11,944.80
- **Portfolio %:** 11.94%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.37 | $-0.13 | +65.0% |
| 2025Q2 | $1.16 | $2.02 | +73.9% |
| 2025Q1 | $-0.65 | $-3.42 | -426.6% |
| 2024Q4 | $2.06 | $1.90 | -7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*